BACKGROUND: Thrombelastography (TEG) allows for rapid global assessment of coagulation function. Our previous work demonstrated that a hypercoagulable state identified by TEG's G value was associated with thromboembolic events in a cohort of critically ill surgical patients despite routine chemoprophylaxis. We hypothesized that a hypercoagulable state could be differentiated into enzymatic or platelet etiology through the use of thrombus velocity curves; specifically the time to maximum rate of thrombus generation (TMRTG) and the novel TEG parameter, delta. (Delta) METHODS: We retrospectively studied 10 critically ill surgical patients receiving thromboprophylaxis for at least 72 h by TEG, using kaolin activated citrated samples. Thrombus velocity curves were plotted for each patient, and delta was calculated as the difference between the TEG parameters R and SP, corresponding to the time to maximum rate of thrombus generation (TMRTG), which reflects the enzymatic contribution to clot formation. The TEG parameter G, (G = 5000 x A/100-A) also was determined for each patient. As G is derived from amplitude (A), it reflects overall net clot strength. A hypercoagulable state was defined as delta < 0.6 min and/or G > 11 dynes/cm(2). RESULTS: A hypercoagulable state was identified via delta in 6 patients (60%); all of whom remained hypercoagulable following heparinase addition, suggesting chemoprophylaxis was ineffective. Of six patients with a hypercoagulable G value, 50% had a normal delta suggesting the presence of platelet hypercoagulability. Delta closely correlated with TMRTG (r = 0.94). However, the varying contribution of platelets to hypercoagulability, was shown by a nonlinear, weak correlation of delta and TMRTG with G (r = 0.11 and r = 0.14, respectively). CONCLUSION: Delta reflects changes in thrombin generation as measured by TMRTG, allowing for differentiation of enzymatic from platelet hypercoagulability. Future studies will be required to validate these findings. Copyright 2010 Elsevier Inc. All rights reserved.
BACKGROUND: Thrombelastography (TEG) allows for rapid global assessment of coagulation function. Our previous work demonstrated that a hypercoagulable state identified by TEG's G value was associated with thromboembolic events in a cohort of critically ill surgical patients despite routine chemoprophylaxis. We hypothesized that a hypercoagulable state could be differentiated into enzymatic or platelet etiology through the use of thrombus velocity curves; specifically the time to maximum rate of thrombus generation (TMRTG) and the novel TEG parameter, delta. (Delta) METHODS: We retrospectively studied 10 critically ill surgical patients receiving thromboprophylaxis for at least 72 h by TEG, using kaolin activated citrated samples. Thrombus velocity curves were plotted for each patient, and delta was calculated as the difference between the TEG parameters R and SP, corresponding to the time to maximum rate of thrombus generation (TMRTG), which reflects the enzymatic contribution to clot formation. The TEG parameter G, (G = 5000 x A/100-A) also was determined for each patient. As G is derived from amplitude (A), it reflects overall net clot strength. A hypercoagulable state was defined as delta < 0.6 min and/or G > 11 dynes/cm(2). RESULTS: A hypercoagulable state was identified via delta in 6 patients (60%); all of whom remained hypercoagulable following heparinase addition, suggesting chemoprophylaxis was ineffective. Of six patients with a hypercoagulable G value, 50% had a normal delta suggesting the presence of platelet hypercoagulability. Delta closely correlated with TMRTG (r = 0.94). However, the varying contribution of platelets to hypercoagulability, was shown by a nonlinear, weak correlation of delta and TMRTG with G (r = 0.11 and r = 0.14, respectively). CONCLUSION: Delta reflects changes in thrombin generation as measured by TMRTG, allowing for differentiation of enzymatic from platelet hypercoagulability. Future studies will be required to validate these findings. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Jeffry L Kashuk; Ernest E Moore; Allison Sabel; Carlton Barnett; James Haenel; Tuan Le; Michael Pezold; Jerry Lawrence; Walter L Biffl; C Clay Cothren; Jeffrey L Johnson Journal: Surgery Date: 2009-10 Impact factor: 3.982
Authors: William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell Journal: Chest Date: 2008-06 Impact factor: 9.410
Authors: Allie M Massaro; Sean Doerfler; Kelsey Nawalinski; Bernard Michel; Nicolette Driscoll; Connie Ju; Hiren Patel; Francis Quattrone; Suzanne Frangos; Eileen Maloney-Wilensky; Michael Sean Grady; Sherman C Stein; Scott E Kasner; Monisha A Kumar Journal: Neurocrit Care Date: 2015-02 Impact factor: 3.210
Authors: Mark M McDonald; Jeremy Wetzel; Stuart Fraser; Andrea Elliott; Ritvij Bowry; Jorge F Kawano-Castillo; Chunyan Cai; Navdeep Sangha; Jessica Messier; Amanda Hassler; Joancy Archeval-Lao; Stephanie A Parker; Mohammad H Rahbar; Evan G Pivalizza; Tiffany R Chang; James C Grotta Journal: J Thromb Thrombolysis Date: 2016-04 Impact factor: 2.300
Authors: Jeffrey N Harr; Ernest E Moore; Max V Wohlauer; Nathan Droz; Miguel Fragoso; Anirban Banerjee; Christopher C Silliman Journal: J Surg Res Date: 2011-04-17 Impact factor: 2.192
Authors: Andrea Elliott; Jeremy Wetzel; Tiffany Roper; Evan Pivalizza; James McCarthy; Cristina Wallace; Mary Jane Hess; Hui Peng; Mohammad H Rahbar; Navdeep Sangha; James C Grotta Journal: Int J Stroke Date: 2012-09-27 Impact factor: 5.266
Authors: Theresa L Chin; Ernest E Moore; Hunter B Moore; Eduardo Gonzalez; Michael P Chapman; John R Stringham; Christopher R Ramos; Anirban Banerjee; Angela Sauaia Journal: Surgery Date: 2014-06-21 Impact factor: 3.982